ARTHUR-D.-LITTLE
2.6.2020 10:02:12 CEST | Business Wire | Press release
Arthur D. Little (ADL) today announced the acquisitions of Cutter Consortium, a business technology research company based in the US, and Presans, a leading player in industrial open innovation based in France. By combining its own expertise with an existing community of independent experts, ADL expands its consulting ecosystem to establish a next-generation value proposition powered by open consulting and open problem solving.
Cutter Consortium (www.cutter.com ) helps organizations navigate digital disruption of business models and leverage emerging technologies for competitive advantage and mission success. Through its research, consulting, training, and executive education – all delivered by globally recognized thought leaders – Cutter delivers innovative solutions to its thousands of clients worldwide. Cutter’s experts have done the ground-breaking work in areas ranging from digital architectures to digital tech, enterprise agility to data analytics, and digital leadership to sustainable innovation. At the heart of its business is a membership service that gives clients valuable access to its experts and their insight.
Presans (www.presans.com ) is a leading data-driven platform dedicated to industrial open innovation and open problem solving. Thanks to cutting-edge technology based on big data and artificial intelligence, as well as a team of fellows (former research and innovation executives) with in-depth knowledge in innovation, Presans leverages a network of over 6 million experts worldwide. Presans provides a variety of high-end open innovation services, contributing to the acceleration of decision-making and removal of scientific and technological roadblocks. Presans has worked for 50+ international industrial groups and delivered more than 100 innovation projects in Europe, the US and the Middle East.
“Arthur D. Little applies an ‘open consulting’ and ‘open problem solving’ approach and brings the best global experts to every assignment to complement its internal strengths,” comments Ignacio García Alves, Chairman and CEO of Arthur D. Little . “We believe the future is open consulting. With the double acquisition of Cutter and Presans, we are able to expand our open consulting ecosystem and open problem solving capabilities, offering access to experts, premium insight and a differentiated experience for our clients, in a seamless way.”
“The Cutter team felt an instant synergy with our colleagues at ADL. We share a focus on innovation, which, in ADL’s case, goes back to its roots, and an emphasis on providing custom, leading-edge solutions. Moreover, ADL’s more than 40 offices in 30 countries has given Cutter an enhanced ability to assist its clients worldwide,” says Karen Coburn, CEO of Cutter Consortium .
“Since its inception at the École Polytechnique's start-up incubator, Presans has always engaged with the best experts in the world, mainly to help its customers solve complex technical problems,” says Albert Meige, Founder of Presans . “Presans now addresses more and more problems at the crossroads of strategy consulting and scientific & technical expertise. The time had therefore come for Presans to strengthen itself by joining forces with Arthur D Little.”
Together with Cutter and Presans, ADL reinforces its position on digital and information technologies, as well as industrial innovation, particularly in breakthrough innovation and convergence problem solving. In addition, through the acquisition of the technological platform of Presans, ADL is accelerating its investments in artificial intelligence and machine learning to develop state-of-the-art offerings for its clients.
Cutter Consortium and Presans will continue to operate under their current brands with the same management teams, while benefiting from ADL’s capabilities, investment, and global exposure.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200602005080/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom